Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 14/20 | 0.45 |
| ▸ | MMP3 | P08254 | 7/20 | 0.45 |
| ▸ | MMP1 | P03956 | 3/20 | 0.44 |
| ▸ | MMP9 | P14780 | 3/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | MMP14 | P50281 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6834453 | 1.00 | GRIK1 (0.52) | GRIK1MMP2MMP3MMP1MMP9 | |
| SCHEMBL5400156 | 0.99 | GRIK1 (0.54) | GRIK1MMP2MMP3MMP1MMP9 | |
| SCHEMBL5400150 | 0.99 | GRIK1 (0.54) | GRIK1MMP2MMP3MMP1MMP9 | |
| SCHEMBL1915090 | 0.92 | CTSS (0.46) | GRIK1MMP2MMP3 | |
| SCHEMBL1914954 | 0.92 | CTSS (0.46) | GRIK1MMP2MMP3 | |
| SCHEMBL1914958 | 0.92 | CTSS (0.46) | GRIK1MMP2MMP3 | |
| SCHEMBL8651824 | 0.88 | GRIK1 (0.42) | GRIK1MMP2MMP3MMP1 | |
| SCHEMBL5680601 | 0.86 | PPARA (0.51) | GRIK1MMP2MMP3 | |
| SCHEMBL8652726 | 0.86 | MME (0.42) | GRIK1MMP2MMP3 | |
| SCHEMBL6834454 | 0.86 | HDAC3 (0.44) | GRIK1MMP2MMP3MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6750363-B2 | Olefination process to itaconate and succinate derivatives | PFIZER, INC. | 2004-06-15 | — | — | US | disclosed |
| US-20020188121-A1 | Novel olefination process to itaconate and succinate derivatives | DERRICK ANDREW MICHAEL (GB) | 2002-12-12 | — | — | US | disclosed |
| US-6452041-B1 | REACTING ALDEHYDE OF FORMULA RCHO, OR A PROTECTED DERIVATIVE THEREOF SUCH AS A HEMIACETAL OR ADDUCT THEREOF SUCH AS A BISULPHITE, WITH A PHOSPHORUS COMPOUND TO OBTAIN SUCCINATE OR ITACONATE DERIVATIVE | PFIZER INC. | 2002-09-17 | — | — | US | disclosed |
| US-20020058832-A1 | Novel olefination process to itaconate and succinate derivatives | PFIZER INC. | 2002-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188121-A1 | Novel olefination process to itaconate and succinate derivatives | HOGA1, OGDH, HADHA | GRIK1 1644/4885MMP2 3089/4885MMP3 3048/4885 |
| US-20020058832-A1 | Novel olefination process to itaconate and succinate derivatives | HOGA1, HADHA, OGDH | GRIK1 2395/4885MMP2 2827/4885MMP3 3007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.